Literature DB >> 3487292

Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus.

A J Swaak, J Groenwold, W Bronsveld.   

Abstract

In a prospective study of 143 patients with systemic lupus erythematosus (SLE) the relation between clinical exacerbations, anti-dsDNA levels, and serum levels of complement components, C1q, C4, C3, C5, and C9 was investigated. In 33 out of these 143 patients a major clinical exacerbation of the disease developed. Evaluation of anti-dsDNA levels in relation to disease activity confirmed our earlier finding that anti-dsDNA levels rose before a major exacerbation and decreased after it. In the remaining 110 SLE patients a nearly constant anti-dsDNA level was seen, but none of these patients experienced a major exacerbation. In the 21 SLE patients who developed deterioration in renal function a decrease of C4 followed by decreases of C1q and C3 levels was seen first, starting about 25 to 20 weeks before the first signs of renal involvement. In the 12 SLE patients who developed an exacerbation without renal involvement an inconsistent profile of the complement components C4, C1q, and C3 was observed. C5 levels were hardly affected at all, while C9 levels were in general higher than normal during the exacerbation, irrespective of the type of exacerbation. These results show that, by following the complement and anti-dsDNA profiles, not only can exacerbations be predicted but also a pointer can be obtained about the pattern of disease well before the first clinical signs of an exacerbation appear.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3487292      PMCID: PMC1001892          DOI: 10.1136/ard.45.5.359

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  12 in total

1.  Immunology of DNA. IV. Quantitative aspects of the Farr assay.

Authors:  L A Aarden; F Lakmaker; E R De Groot
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

2.  Serum complement component levels in human glomerulonephritis.

Authors:  E J Lewis; C B Carpenter; P H Schur
Journal:  Ann Intern Med       Date:  1971-10       Impact factor: 25.391

3.  Immunologic factors and clinical activity in systemic lupus erythematosus.

Authors:  P H Schur; J Sandson
Journal:  N Engl J Med       Date:  1968-03-07       Impact factor: 91.245

4.  Serial complement component alterations in acute glomerulonephritis and systemic lupus erythematosus.

Authors:  P F Kohler; R Ten Bensel
Journal:  Clin Exp Immunol       Date:  1969-02       Impact factor: 4.330

5.  Properties of bacteriophage PM2: a lipid-containing bacterial virus.

Authors:  R T Espejo; E S Canelo
Journal:  Virology       Date:  1968-04       Impact factor: 3.616

Review 6.  Clinical applications of complement measurements in rheumatic diseases.

Authors:  I M Goldstein
Journal:  Am J Med Sci       Date:  1975 Mar-Apr       Impact factor: 2.378

7.  Significance of persisting serologic abnormalities in SLE.

Authors:  R W Lightfoot; G R Hughes
Journal:  Arthritis Rheum       Date:  1976 Sep-Oct

8.  Anti-dsDNA and complement profiles in systemic lupus erythematosus.

Authors:  A J Swaak; J Groenwold; W Bronsveld; J Douma; T E Feltkamp
Journal:  Neth J Med       Date:  1981       Impact factor: 1.422

9.  Studies of serum complement in the hypocomplementaemic nephritides.

Authors:  D G Williams; D K Peters; J Fallows; A Petrie; O Kourilsky; L Morel-Maroger; J S Cameron
Journal:  Clin Exp Immunol       Date:  1974-11       Impact factor: 4.330

10.  Alper CA, Rosen FS: Studies of the in vivo behavior of human C'3 in normal subjects and patients.

Authors:  C A Alper; F S Rosen
Journal:  J Clin Invest       Date:  1967-12       Impact factor: 14.808

View more
  48 in total

Review 1.  The use of laboratory tests in the diagnosis of SLE.

Authors:  W Egner
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

Review 2.  Complement as a source of biomarkers in systemic lupus erythematosus: past, present, and future.

Authors:  Chau-Ching Liu; Joseph M Ahearn; Susan Manzi
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

3.  Kidney Outcomes and Risk Factors for Nephritis (Flare/De Novo) in a Multiethnic Cohort of Pregnant Patients with Lupus.

Authors:  Jill P Buyon; Mimi Y Kim; Marta M Guerra; Sifan Lu; Emily Reeves; Michelle Petri; Carl A Laskin; Michael D Lockshin; Lisa R Sammaritano; D Ware Branch; T Flint Porter; Allen Sawitzke; Joan T Merrill; Mary D Stephenson; Elisabeth Cohn; Jane E Salmon
Journal:  Clin J Am Soc Nephrol       Date:  2017-04-11       Impact factor: 8.237

4.  Prior anti-dsDNA antibody status does not predict later disease manifestations in systemic lupus erythematosus.

Authors:  Loes van den Berg; Hans Nossent; Ole Rekvig
Journal:  Clin Rheumatol       Date:  2005-11-23       Impact factor: 2.980

5.  Use of recombinant RNP peptides 70K and A in an ELISA for measurement of antibodies in mixed connective tissue disease: a longitudinal follow up of 18 patients.

Authors:  D J de Rooij; W J Habets; L B van de Putte; M H Hoet; A L Verbeek; W J van Venrooij
Journal:  Ann Rheum Dis       Date:  1990-06       Impact factor: 19.103

Review 6.  Anti-DNA antibodies as early predictor for disease exacerbations in SLE. Guideline for treatment?

Authors:  P E Spronk; H Bootsma; C G Kallenberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

7.  The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation.

Authors:  H Bootsma; P E Spronk; E J Ter Borg; E J Hummel; G de Boer; P C Limburg; C G Kallenberg
Journal:  Ann Rheum Dis       Date:  1997-11       Impact factor: 19.103

8.  Serum levels of soluble forms of T cell activation antigens CD27 and CD25 in systemic lupus erythematosus in relation with lymphocytes count and disease course.

Authors:  A J Swaak; R Q Hintzen; V Huysen; H G van den Brink; J T Smeenk
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980

9.  A long-term immunological study of childhood onset systemic lupus erythematosus.

Authors:  C K Ting; K H Hsieh
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

Review 10.  New advances in measurement of complement activation: lessons of systemic lupus erythematosus.

Authors:  Chau-Ching Liu; Susan Manzi; Natalya Danchenko; Joseph M Ahearn
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.